Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 17/20 | 0.67 |
| ▸ | FAP | Q12884 | 3/20 | 0.66 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.66 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.66 |
| ▸ | DPP7 | Q9UHL4 | 3/20 | 0.55 |
| ▸ | PREP | P48147 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15024754 | 0.83 | DPP4 (0.69) | DPP4FAPDPP8DPP9DPP7 | |
| SCHEMBL7795161 | 0.82 | DPP4 (0.71) | DPP4FAPDPP8DPP9DPP7 | |
| SCHEMBL3189715 | 0.81 | DPP4 (1.00) | DPP4FAPDPP8DPP9DPP7 | |
| SCHEMBL12354534 | 0.81 | DPP4 (0.69) | DPP4FAPDPP8DPP9DPP7 | |
| SCHEMBL15855961 | 0.81 | DPP4 (0.69) | DPP4FAPDPP8DPP9DPP7 | |
| Vildagliptin SCHEMBL10031674 | 0.80 | DPP4 (1.00) | DPP4FAPDPP8DPP9PREP | |
| Vildagliptin SCHEMBL16153676 | 0.80 | DPP4 (1.00) | DPP4FAPDPP8DPP9PREP | |
| Vildagliptin SCHEMBL16823370 | 0.80 | DPP4 (1.00) | DPP4FAPDPP8DPP9PREP | |
| Vildagliptin SCHEMBL671629 | 0.80 | DPP4 (1.00) | DPP4FAPDPP8DPP9PREP | |
| Vildagliptin SCHEMBL16155482 | 0.80 | DPP4 (1.00) | DPP4FAPDPP8DPP9PREP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140248345-A1 | PHARMACEUTICAL COMPOSITIONS OF COMBINATIONS OF DIPEPTIDYL PEPTIDASE-4 INHIBITORS WITH ATORVASTATIN | MERCK SHARP & DOHME CORP. | 2014-09-04 | — | — | US | disclosed |
| US-8414921-B2 | Pharmaceutical compositions of combinations of dipeptidyl peptidase-4 inhibitors with metformin | MERCK SHARP & DOHME CORP. (US) | 2013-04-09 | — | — | US | disclosed |
| US-20120201885-A1 | PHARMACEUTICAL COMPOSITIONS OF COMBINATIONS OF DIPEPTIDYL PEPTIDASE-4 INHIBITORS WITH PIOGLITAZONE | MERCK SHARP & DOHME CORP | 2012-08-09 | — | — | US | disclosed |
| US-20120059011-A1 | PHARMACEUTICAL COMPOSITIONS OF COMBINATIONS OF DIPEPTIDYL PEPTIDASE-4 INHIBITORS WITH PIOGLITAZONE | MERCK SHARP & DOHME CORP. | 2012-03-08 | — | — | US | disclosed |
| US-20100184758-A1 | BETA CARBOLINE DERIVATIVES AS ANTIDIABETIC COMPOUNDS | MERCK SHARP & DOHME CORP. | 2010-07-22 | — | — | US | disclosed |
| US-20090105265-A1 | Pharmaceutical Compositions of Combinations of Dipeptidyl Peptidase-4 Inhibitors With Metformin | MERCK & CO., INC. | 2009-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100184758-A1 | BETA CARBOLINE DERIVATIVES AS ANTIDIABETIC COMPOUNDS | GPR119, SSTR3, SSTR2 | DPP4 267/4885FAP 4218/4885DPP8 773/4885 |
| US-20140248345-A1 | PHARMACEUTICAL COMPOSITIONS OF COMBINATIONS OF DIPEPTIDYL PEPTIDASE-4 INHIBITORS WITH ATORVASTATIN | DPP4, DPP7, DPP3 | DPP4 1/4885FAP 96/4885DPP8 5/4885 |
| US-20120059011-A1 | PHARMACEUTICAL COMPOSITIONS OF COMBINATIONS OF DIPEPTIDYL PEPTIDASE-4 INHIBITORS WITH PIOGLITAZONE | DPP4, DPP7, DPP3 | DPP4 1/4885FAP 26/4885DPP8 5/4885 |
| US-20120201885-A1 | PHARMACEUTICAL COMPOSITIONS OF COMBINATIONS OF DIPEPTIDYL PEPTIDASE-4 INHIBITORS WITH PIOGLITAZONE | DPP4, DPP7, DPP3 | DPP4 1/4885FAP 35/4885DPP8 5/4885 |
| US-20090105265-A1 | Pharmaceutical Compositions of Combinations of Dipeptidyl Peptidase-4 Inhibitors With Metformin | DPP4, DPP7, DPP3 | DPP4 1/4885FAP 19/4885DPP8 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.